



Measure Applications Partnership
Clinician Workgroup In-Person Meeting
December 12, 2017 | 8:00 am –4:30 pm ET

Participant Instructions:

Materials for all MAP Workgroup meetings are available on the [NQF Public SharePoint Page](#) as well as the project web pages.

Participant/Public: (877) 793-5566

Web Link: <http://nqf.commpartners.com/se/Rd/Mt.aspx?942049>

Registration Link: <https://www.cvent.com/events/measure-applications-partnership-clinician-workgroup-meeting/registration-8d8c0cd1e1864af28a478f0e1bb4505e.aspx?fgp=true>

Meeting Objectives:

- Review and provide input on Measures Under Consideration for federal programs applicable to clinicians and ACOs.
- Discuss strategic issues related to clinician and ACO care

8:00 am **Breakfast**

8:30 am **Welcome, Introductions, Disclosures of Interest, Review of Meeting Objectives**

Bruce Bagley, Workgroup Chair

Amy Moyer, Workgroup Chair

John Bernot, Senior Director, NQF

Elisa Munthali, Acting Senior Vice President, NQF

8:45 am **CMS Opening Remarks and Review of Meaningful Measures Framework**

Pierre Yong, CMS

9:05 am **Overview of Pre-Rulemaking Approach**

Hiral Dudhwala, Project Manager, NQF

- MAP will use a three step approach:
 - Provide program overview
 - Review current measures
 - Evaluate Measures Under Consideration (MUC) for what they would add to the program measure set
- Review of decision categories and guidance on refine and resubmit

9:20 am **Overview of the MIPS Cost Measures**

Theodore Long, CMS

Reena Duseja, CMS

- 9:35 am Opportunity for Public Comment on Cost/Resource Use Measures Under Consideration**
- 9:40 am Pre-Rulemaking Input on the MIPS Measures Under Consideration- Cost/Resource Use**
Lead Discussant - Scott Friedman (American Academy of Ophthalmology)
Lead Discussant - Stephanie Glier (Pacific Business Group on Health)
- Routine Cataract Removal with Intraocular Lens (IOL) Implantation (MUC17-235)
 - Screening/Surveillance Colonoscopy (MUC17-256)
 - Knee Arthroplasty (MUC17-261)
 - ST-Elevation Myocardial Infarction (STEMI) with Percutaneous Coronary Intervention (PCI) (MUC17-262)
 - Revascularization for Lower Extremity Chronic Critical Limb Ischemia (MUC17-263)
 - Elective Outpatient Percutaneous Coronary Intervention (PCI) (MUC17-359)
 - Intracranial Hemorrhage or Cerebral Infarction (MUC17-363)
 - Simple Pneumonia with Hospitalization (MUC17-365)
- 10:45 am Break**
- 11:00 am Opportunity for Public Comment on Opioid Use Measures Under Consideration**
- 11:05 am Pre-Rulemaking Input on the MIPS Measure Under Consideration- Opioid Use**
Lead Discussant - Leslie Zun (SME)
Lead Discussant - Ann Greiner (Patient-Centered Primary Care Collaborative)
- Continuity of Pharmacotherapy for Opioid Use Disorder (MUC17-139)
- 11:15 am Opportunity for Public Comment on HIV Measure Under Consideration**
- 11:20 am Pre-Rulemaking Input on the MIPS Measure Under Consideration- HIV**
Lead Discussant - Helen Burstin (Council of Medical Specialty Societies)
Lead Discussant - Charlene Ngamwajasat (Primary Care Information Project)
- HIV Screening (MUC17-367)
- 11:30 pm Opportunity for Public Comment on Functional Status Measures Under Consideration**
- 11:35 pm Pre-Rulemaking Input on the MIPS Measures Under Consideration - Functional Status**
Lead Discussant - Eric Whitacre (Subject Matter Expert (SME))
Lead Discussant - Kevin Bowman (Anthem)
- Average change in functional status following lumbar spine fusion surgery (MUC17-168)
 - Average change in functional status following total knee replacement surgery (MUC17-169)
 - Average change in functional status following lumbar discectomy laminotomy surgery (MUC17-170)
 - Average change in leg pain following lumbar spine fusion surgery (MUC17-177)

PAGE 3

- 12:15 pm** **Lunch**
- 1:00 pm** **MAP Rural Health Introduction and Presentation**
Karen Johnson, Senior Director, NQF
- Introduce and discuss the newly created MAP Rural Health Workgroup
- 1:20 pm** **Opportunity for Public Comment on Urology Measure Under Consideration**
- 1:25 pm** **Pre-Rulemaking Input on the MIPS Measure Under Consideration- Urology**
Lead Discussant - Scott Furney (Carolina's Healthcare System)
Lead Discussant - Patti Wahl (St. Louis Area Business Health Coalition)
- International Prostate Symptom Score (IPSS) or American Urological Association-Symptom Index (AUA-SI) change 6-12 months after diagnosis of Benign Prostatic Hyperplasia (MUC17-239)
- 1:40 pm** **Opportunity for Public Comment on Vaccination Measure Under Consideration**
- 1:45 pm** **Pre-Rulemaking Input on the MIPS Measure Under Consideration- Vaccination**
Lead Discussant - Dayo Jagun (Genentech)
Lead Discussant - Dianne Padden (American Association of Nurse Practitioners)
- Zoster (Shingles) Vaccination (MUC17-310)
- 2:00 pm** **Break**
- 2:15 pm** **Opportunity for Public Comment on Appropriate Use Measures Under Consideration**
- 2:20 pm** **Pre-Rulemaking Input on the MIPS Measures Under Consideration- Appropriate Use**
Lead Discussant - David Seidenwurm (American College of Radiology)
Lead Discussant - Robert Krughoff (Consumers' Checkbook/Center for the Study of Services)
- Appropriate Use of DXA Scans in Women Under 65 Years Who Do Not Meet the Risk Factor Profile for Osteoporotic Fracture (MUC17-173)
- 2:35 pm** **Opportunity for Public Comment on Vascular Measures Under Consideration**
- 2:40 pm** **Pre-Rulemaking Input on the MIPS and MSSP Measures Under Consideration- Vascular**
Lead Discussant - William Van Decker (American College of Cardiology)
Lead Discussant - Beth Averbeck (Health Partners Inc.)
- Optimal Vascular Care (MUC17-194)
 - Ischemic Vascular Disease Use of Aspirin or Anti-platelet Medication (MUC17-234)*
 - Patient reported and clinical outcomes following ilio-femoral venous stenting (MUC17-345)
- *This measure is under consideration for both MIPS and MSSP.
- 3:10 pm** **Opportunity for Public Comment on Diabetes Measures Under Consideration**

PAGE 4

3:15 pm

**Pre-Rulemaking Input on the MIPS and MSSP Measures Under Consideration-
Diabetes**

Lead Discussant - Amy Nguyen (CAPG)

Lead Discussant - Dale Shaller (SME)

- Optimal Diabetes Care (MUC17-181)*
- Diabetes A1c Control (< 8.0) (MUC17-215)*

*This measure is under consideration for both MIPS and MSSP.

3:30 pm

Input on Measure Removal Criteria

Pierre Yong, CMS

4:00 pm

Opportunity for Public Comment

4:15 pm

Summary of Day and Next Steps

Bruce Bagley, Workgroup Chair

Amy Moyer, Workgroup Chair

Madison Jung, Project Analyst, NQF

4:30 pm

Adjourn